Email updates

Keep up to date with the latest news and content from BMC Infectious Diseases and BioMed Central.

This article is part of the supplement: Abstracts from the First International Science Symposium on HIV and Infectious Diseases (HIV SCIENCE 2012)

Open Access Poster presentation

Studies on the extended spectrum beta lactamases activity in isolates from diabetes patients

AL Dorothy Kalyani12*, T Palaniappan1, V Mohan1 and T Sundararaj3

Author Affiliations

1 Dr. Mohan’s Diabetes Specialities Centre, Gopalapuram, Chennai, India

2 Meenakshi Ammal Dental College, Maduravoyal, Chennai, India

3 Jasmn Laboratory, Jasmn Education & Research Foundation, Perungudi, Chennai, India

For all author emails, please log on.

BMC Infectious Diseases 2012, 12(Suppl 1):P86  doi:10.1186/1471-2334-12-S1-P86

The electronic version of this article is the complete one and can be found online at:

Published:4 May 2012

© 2012 Kalyani et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Extended spectrum beta-lactamases (ESBLs) are enzymes produced by some gram negative bacilli that mediate resistance to extended-spectrum cephalosporins and aztreonam. ESBLs are commonly recognized in a variety of Enterobacteriaceae and Pseudomonas aeruginosa isolates. This study focused on the prevalence of ESBL producing strains from diabetes patients and their antimicrobial correlation.


ESBL activity studied in different gram negative bacteria isolated from xxx urine samples were subjected to antimicrobial susceptibility testing by Kirby-Bauer method as per CLSI guidelines antimicrobials agents (Cefpodoxime, Ceftazidime, Cefotaxime, & Ceftriaxone) selected for testing along with combinations of antimicrobials Cefoperazone sulbactam (CFS), Piperacillin-tazobactam (PT) Amoxyclav (AC) were compared for their ability to detect ESBL producers phenotypically.


Among 4446 samples processed 3426 showed ESBL activity in different gram negative bacilli 85% in E.coli, 7% Klebsiella pneumoniae, 0.5% Klebsiella oxytoca, 2.3% Pseudomonas aeruginosa, 0 .5% Citrobacter koseri, 1% in Proteus mirabilis.


There is a significant increase in the prevalence of ESBL E.coli when compared to other gram negative isolates. Detection of ESBL by phenotypic method in the absence of molecular testing is considered as timely, affordable and appropriate measure in deciding the antibiotic therapy.